Pharmacologic Substance
Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis
Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.
Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis
Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.
AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership
AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.
Cytokinetics Unveils Aficamten Data, Gears Up for Market Competition Against Camzyos
Cytokinetics, Aficamten, Camzyos, clinical data, cardiovascular disease, myotonic dystrophy, heart failure, commercial strategy, market competition.
Ajax Pharmaceuticals Secures $95 Million for JAK Inhibitor Drug Development
Ajax Pharmaceuticals, JAK inhibitors, drug development, funding, investment, inflammatory diseases, autoimmune disorders, cancer.
Novel Monthly Hemophilia A Treatment by Novos Poses Challenge to Roche’s Hemlibra
Hemophilia A, Novos, Roche, Hemlibra, monthly treatment, performance, challenge.
Moderna’s Diversification Strategy Hindered by FDA Delay in RSV Vaccine Review
Moderna, FDA, RSV vaccine, diversification strategy, vaccine review, delay
Shionogi Acquires Maze’s Pompe Disease Drug Following FTC’s Sanofi Deal Halt
Shionogi, Maze, Pompe disease, drug acquisition, FTC, Sanofi, $150 million
Revolutionizing Medicine: The Evolution and Future of Cell and Gene Therapy Manufacturing
Cell therapy manufacturing, gene therapy manufacturing, biomanufacturing, advanced therapies, CAR-T cell therapy, stem cell therapy, viral vectors, bioreactors, automation, scale-up, regulatory compliance, personalized medicine.
Moderna’s RSV Vaccine Decision Postponed by FDA to Late May
FDA, Moderna, RSV vaccine, decision, delay, May